Article
SF3B1 mutation-mediated sensitization to H3B-8800 splicing inhibitor in chronic lymphocytic leukemia.
Life science alliance - 1 Nov 2023
López-Oreja Irene, Gohr André, Playa-Albinyana Heribert, Giró Ariadna, Arenas Fabian, Higashi Morihiro, Tripathi Rupal, López-Guerra Mònica, Irimia Manuel, Aymerich Marta, Valcárcel Juan, Bonnal Sophie, Colomer Dolors
Abstract excerpt
Splicing factor 3B subunit 1 (SF3B1) is involved in pre-mRNA branch site recognition and is the target of antitumor-splicing inhibitors. Mutations in SF3B1 are observed in 15% of patients with chronic lymphocytic leukemia (CLL) and are associated with poor prognosis, but their pathogenic mechanisms remain poorly understood. Using deep RNA-sequencing data from 298 CLL tumor samples and isogenic SF3B1 WT and...
Topics
Join the communities discussing this publication.